TRT Benefits and Limits: What the Evidence Supports

Keep the supported and unsupported outcomes separate

AUA Statement 14, a Moderate Recommendation with Grade B evidence, says therapy may improve erectile function, low sex drive, anemia, bone mineral density, lean body mass, and depressive symptoms. Statement 15, with the same grade, says evidence is inconclusive for cognitive function, diabetes measures, energy, fatigue, lipid profiles, and quality of life. AUA guideline The word may matters. These are not promises.

ACP Recommendation 2 suggests that clinicians not start testosterone treatment in men with age-related low testosterone for energy, vitality, physical function, or cognition. The recommendation is conditional and based on low-certainty evidence. ACP guideline

Where ACP supports a discussion

ACP Recommendation 1a suggests discussing treatment with men who have age-related low testosterone and sexual dysfunction and want to improve sexual function. It calls for discussion of benefits, harms, costs, and preferences and describes the evidence as low certainty. Recommendation 1b says clinicians should reevaluate symptoms within 12 months and periodically, discontinuing treatment when sexual function does not improve. ACP guideline

AUA similarly says clinicians should discuss stopping after three to six months when testosterone normalizes but symptoms or signs do not improve. AUA guideline Both guidelines treat treatment as something to reassess, not an automatic indefinite commitment.

Diagnosis comes first, and sometimes another treatment comes first

The Endocrine Society says therapy has clear benefits for men with appropriately diagnosed hypogonadism caused by disease affecting the testes, pituitary, or hypothalamus. It also says weight loss is typically first-line when overweight or obesity, with BMI above 27, is the identified cause and no other cause is found. Symptoms alone are not diagnostic, and reversible contributors should be considered. Endocrine Society

FDA says approved testosterone products are for men with absent or low testosterone together with an associated medical condition and are not approved for a low level without an associated condition. FDA testosterone information

The cardiovascular evidence, stated completely

TRAVERSE followed more than 5,200 men assigned to AndroGel 1.62% or placebo. Major adverse cardiovascular events occurred in 7.0 percent of the testosterone group and 7.3 percent of the placebo group. FDA concluded that the trial did not show a new cardiovascular safety signal. FDA testosterone information FDA later removed class-wide boxed-warning language about increased cardiovascular risk while requiring blood-pressure warnings. FDA class-wide notice

That finding does not establish overall safety. The Endocrine Society says TRAVERSE found no meaningful increase in heart attack and stroke over one to four years but also found roughly a 50 percent relative increase in pulmonary embolism and more fractures among testosterone-treated men. It says long-term safety, including prostate cancer safety, remains unestablished. Endocrine Society

AUA says low testosterone itself is a cardiovascular risk factor and also says it cannot be stated definitively whether therapy increases or decreases cardiovascular-event risk. AUA advises against starting therapy for three to six months after a cardiovascular event. AUA guideline

Risks and limitations in product labeling

The AndroGel label describes increased hematocrit, venous thromboembolism, blood-pressure increases, possible worsening of BPH, prostate evaluation, possible worsening of sleep apnea, and suppression of spermatogenesis that may lead to azoospermia. It is not recommended for uncontrolled hypertension. AndroGel label

In TRAVERSE, venous thromboembolism occurred in 1.7 percent of the testosterone group and 1.2 percent of the placebo group. Pulmonary embolism occurred in 0.9 percent and 0.5 percent, respectively. AndroGel label XYOSTED also warns about depression and suicide and directs patients and caregivers to seek medical attention for suicidal thoughts or behavior, worsening depression, anxiety, or other mood changes. XYOSTED label

What changed in 2026, and what did not

In June 2026, FDA requested removal of the limitation stating that safety and efficacy in age-related hypogonadism have not been established and requested revisions to prostate cancer and BPH safety information. FDA testosterone information Reuters reported that the proposal would narrow the prostate-cancer contraindication and retain evaluation and monitoring. Reuters

Individual labels change on their own schedules. The AndroGel 1.62% label revised October 2025 still carried the age-related limitation and contraindicated known or suspected prostate carcinoma when verified for this page. AndroGel label A requested labeling change is not a recommendation for any individual.

Questions to ask a licensed clinician

• Which specific outcome is treatment intended to improve, and how strong is the evidence for it?
• Have reversible contributors and the cause of low results been evaluated?
• If weight is a contributor, what first-line weight-management approach is appropriate?
• What risks matter most given the medical and family history?
• How would benefit and safety be reassessed, and what would lead to stopping treatment?
• How do the pulmonary embolism, fracture, blood-pressure, fertility, and prostate uncertainties affect the decision?

Limits and urgent symptoms

This article is general education, not medical advice, diagnosis, treatment, or a recommendation to start or stop therapy. Seek immediate care for chest pain, shortness of breath, or new leg swelling, or call 911. AndroGel label XYOSTED label

FDA requested testosterone labeling updates in June 2026 and the Endocrine Society published a new statement in July 2026. Product labels are being revised individually. Content verified August 26, 2026.